【Objective】This study aims to investigate whether rutecarpine has an effect on calcification of VSMC and its underlying mechanism. 【Methods】 In vitro model of rat VSMC calcification was used in this study. Rutecarpine at different concentrations was used to treat cultured rat VSMC. The expression of Runx2，BMP2 and Osterix was analyzed by qRT-PCR and mineral deposition was detected by alizarin red staining. In addition，we examined the effect of rutecarpine on Sirtuin-1（Sirt1）expression in VSMC and the effect of Sirt1 inhibitor on VSMC calcification.【Results】Alizarin red staining and calcium content assay showed that rutecarpine at different concentrations significantly reduced calcification of rat VSMC induced by high phosphorus and high calcium（136±10，75±6，52±6，31±5.29，P < 0.05）. Usage of rutecarpine decreased the activity of ALP，an osteogenic differentiation molecular marker，and down-regulated the expression of Runx2（2.85±0.25，1.75±0.18，1.62±0.13，1.36±0.16，P < 0.05），BMP2（3.2±0.32，1.85±0.17，1.65±0.15，1.43±0.12，P < 0.05）and Osterix（2.60±0.27，1.82±0.16，1.55±0.15，1.36±0.17，P < 0.05），suggesting that rutecarpine inhibited osteogenic differentiation of VSMC. In addition ，high phosphorus and high calcium down-regulated the expression of Sirt1 in VSMC. qRT-PCR and western blot analysis confirmed that rutecarpine up- regulated the expression of Sirt1 at both mRNA（0.35±0.06，0.75±0.11；0.22±0.08，0.87±0.13，P < 0.05）and protein levels（0.38±0.09，0.71±0.13 ，P<0.05）. Quantification of calcium content analysis showed inhibition of Sirt1 by EX-527 blocked the inhibitory effect of rutecarpine on VSMC calcification（138±13，36±7，87±8，P < 0.05）.【Conclusion】We demonstrate that rutecarpine attenuates VSMC calcification via up-regulation of Sirt1.